This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Medical Stocks to Consider as Markets Take a Breather
by Shaun Pruitt
These top medical stocks may be able to provide defensive safety after President Trump's tariff hikes and July's unfavorable jobs report led to a market selloff.
Here's Why Tenet Healthcare (THC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Tenet (THC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
by Zacks Equity Research
Humana's Q2 earnings fall year over year on a declining membership base. Notably, 2025 adjusted EPS is currently forecasted at around $17.00, up from the earlier view of around $16.25.
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
by Zacks Equity Research
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is It Worth Investing in Tenet (THC) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
by Zacks Equity Research
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Is Tenet Healthcare (THC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Tenet (THC)
by Zacks Equity Research
Tenet (THC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
New Strong Buy Stocks for July 25th
by Zacks Equity Research
PHIN, MBWM, THC, RVLV and PHAR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2025.
Best Value Stocks to Buy for July 25th
by Zacks Equity Research
EDNMY, THC and MBWM made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 25, 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is the Options Market Predicting a Spike in Tenet Healthcare Stock?
by Zacks Equity Research
Investors need to pay close attention to THC stock based on the movements in the options market lately.
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
by Zacks Equity Research
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
by Zacks Equity Research
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Tenet (THC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Tenet (THC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tenet Healthcare (THC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of +41.55% and +2.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health and Community Health Systems
by Zacks Equity Research
Despite industry pressures, HCA, THC, UHS, and CYH are leveraging M&A, tech, and rising demand to drive resilient growth.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
by Zacks Equity Research
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
Hospital Market May Be Sick, But These 4 Stocks Are Healthy
by Kaibalya Pravo Dey
HCA, THC, UHS, and CYH are showing strength through smart expansions and solid earnings despite hospital industry headwinds.
HCA Healthcare (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Tenet Healthcare (THC) concluded the recent trading session at $175.14, signifying a +1.01% move from its prior day's close.
Insights Into Tenet (THC) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.